Related references
Note: Only part of the references are listed.Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
Anna-Maria Hoffmann-Vold et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Dinesh Khanna et al.
LANCET RESPIRATORY MEDICINE (2020)
Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II
Elizabeth R. Volkmann et al.
ACR OPEN RHEUMATOLOGY (2020)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Oliver Distler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Interstitial lung disease in systemic sclerosis: current and future treatment
Roberto Giacomelli et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin et al.
LANCET RESPIRATORY MEDICINE (2016)
Mortality and survival in systemic sclerosis: Systematic review and meta-analysis
Manuel Rubio-Rivas et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2014)
Changes in causes of death in systemic sclerosis, 1972-2002
Virginia D. Steen et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Cyclophosphamide versus placebo in scleroderma lung disease
Donald P. Tashkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)